Business
Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells
Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., March 17, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells. Study results indicate a 35% prolonged survival rate in mice exposed to RCC-33 in comparison with sham control mice, as shown by Kaplan-Meier survival curve analysis, P-value = 0.08 (Figure 1).\n\n \n \n \n \n \n \n\n \nThe mean survival rate observed in the experimental group was 31 days from treatment initiation vs. 23 days in the control group, reflecting a 35% increase in survival rate in the treatment group. The current results, taken together with previously obtained results of 33% reduction in tumor volume in the RCC-33 exposed group, further support the promising potential role of RCC-33 as part of the treatment armamentarium against colorectal cancer in the future. Company is aiming to schedule a pre-IND meeting with the US Food and Drug Administration by next quarter and start Phase 1/2a trials by beginning of 2022.\n\"Cannabics™ RCC-33 is the first proprietary antitumor formulation we have released for in-vivo testing. This, out of a developing pipeline of additional antitumor drug candidates that we are currently working on,\" said Eyal Barad, Cannabics Pharmaceuticals' Co-founder and CEO.  \"Our aim with RCC-33 is to help a large and growing group of patients and assist in fulfilling a significant unmet need in an estimated $10 billion market.\"\nGabri...